This activation enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying, and reduces appetite through central nervous system pathways
Combining with DPP-4 inhibitors is generally not recommended, as both drug classes work on the incretin system Adding basal insulin for those with more significant hyperglycaemia, which can be used alongside GLP-1 medications (with careful monitoring for hypoglycaemia) Switching to insulin therapy entirely may be necessary for those with advanced beta cell failure For weight management , when GLP-1 medications don't produce adequate weight loss, alternatives include: Orlistat , a lipase inhibitor that reduces fat absorption, though weight loss is typically modest (2-3 kg on average) Naltrexone-bupropion (Mysimba), which works on appetite centres through different pathways
The Future of GLP-1 Research and Therapeutics The field of GLP-1-based therapy is evolving at a breathtaking pace
Its fair to assume that in GLP-1 patients undergoing significant weight loss it will be even less predictable, Byrne said.
Retatrutide might be the next wonder drug for non-diabetic weight loss
[1] [37] For other GLP-1 receptor agonists, clinically significant effects on oral contraceptive efficacy have not been demonstrated, but patients should check their specific medication's SmPC
